TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically proven sarcoidosis from any site (noncaseating granulomas without other causes).~2. Diagnosis of active sarcoidosis (Sec. 5.5.4.t) clinical stage II by Chest X-ray (CXR).~3. Forced Vital Capacity (FVC) \>45% and Diffusing Capacity for Carbon Monoxide (DLCO) \>50% of predicted values.~4. Evidence of active sarcoidosis (see criteria above)~5. Able and willing to complete all study procedures (e.g., bronchoscopy, post-drug surveillance)~6. Age: 18+ years old (prevalence greatest in young adults; pediatric maraviroc safety not established).~7. Not on immunosuppression for sarcoidosis at the time of recruitment, (e.g., steroids, tumor necrosis factor alpha (TNF-a) blockade)~8. Liver function (transaminases, bilirubin), coagulation (International Normalized Ratio (INR), partial thromboplastin time (PTT), platelet count), blood urea nitrogen (BUN), creatinine, and white blood count (WBC) within normal limits.~9. If female: negative pregnancy test, agreement to use reliable contraception if of childbearing potential 30 days prior and for 30 days after study completion (drug safety during pregnancy not established).~10. Negative HIV and HBsAg tests~Exclusion Criteria:~1. Diagnosis of infection based upon clinical evaluation and/or microbial testing.~2. The diagnosis of any disease involving the heart, lungs, liver (HVC), kidney, hematologic, endocrine, or Gl systems which, in the judgment of the PI, would pose an undue risk to the subject if they participated in this study. This includes but is not limited to diabetes, uncontrolled hypertension, liver disease (HVC), or history of malignancy.~3. Medications that will either inhibit or induce CYP3A4 (including St John's Wort)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- sarcoidosis stage II (Type: EXPERIMENTAL): All subjects with active stage II sarcoidosis with or without skin disease will receive the drug maraviroc 300mg to be taken orally twice a day for 6 weeks duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: AIH Risk Stratification With Multiparametric MRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing management for AIH being considered for treatment cessation~* Patients diagnosed with AIH, are treatment naïve, and will be undergoing biopsy as per clinical pathway~* Diagnostic biopsy prior to cessation of treatment (where possible)~* 18+ years of age.~* Ability to give informed consent~Exclusion Criteria:~* Any contraindication to MRI scanning~* Any clinically significant medical or psychiatric condition

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Naive (Type: None): 20 patients with AIH will be recruited that will be treatment naive at the time of recruitment.
- Treatment cessation review (Type: None): 77 AIH patients will be recruited who will have been on treatment for the past 18-24 months and will be coming in to meet their physician to review treatment cessation options

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet criteria for a diagnosis of ITP as specified by ASH guidelines~* Must be within 30 days after diagnosis of ITP at the time of randomization (diagnosis of ITP starts with first platelet count ≤ 100,000/μl)~* Platelet count ≤ 30,000/μl at the time ITP is diagnosed, and/or at some time between the diagnosis of ITP and study entry~* Platelet count ≤ 150,000/μl at the time of randomization~* Age ≥ 15 years~* If bone marrow examination is available, it must be compatible with ITP~* Subjects, or their legal guardians, must have the ability to provide informed consent~Exclusion Criteria:~* Rituximab therapy or splenectomy for ITP or for any other cause within the previous 8 weeks.~* Known HIV infection~* Known HCV infection~* Known systemic lupus erythematosus~* Pregnancy or breastfeeding~* Insulin-requiring diabetes mellitus~* Previous exposure to prednisone for ITP at a dose ≥ 1.5 mg/kg prednisone/day for ≥ 1 week prior to study entry~* Ongoing use of treatments that are known to inhibit platelet function, e.g. aspirin~* Anything that in the opinion of the investigator is likely to interfere with participation in the study~* Persons previously randomized in the ITP\^2 study~* Persons currently enrolled in other interventional clinical trials~* Exposure to thrombopoietic agent prior to study entry~* Previous exposure to dexamethasone for the treatment of ITP at a dose of 30 mg/day or greater for subjects \< 60 kg or 40 mg/day or greater for subjects \>= 60 kg for at least four days

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose pulse dexamethasone (Type: EXPERIMENTAL): None
- Standard prednisone therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Deutsches Dual Therapy Stent Register

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients has at least one coronary lesion, suitable for PCI treatment with the Combo stent in accordance with European Society of Cardiology Guidelines and local Guidelines of the Deutsche Gesellschaft für Kardiologie for drug eluting stents~Exclusion Criteria:~* Patient has previously received murine therapeutic antibodies and exhibited sensitization through the production of Human Anti- Murine Antibodies (HAMA)~* Patient in whom anti-platelet and/or anticoagulant therapy is contraindicated~* Patient in whom a complete inflation of the angioplasty balloon or correct stent placement is thought to be inhibited

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study of ABBV-8E12 in Early Alzheimer's Disease (AD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects with early AD who complete Study M15-566 (NCT02880956), meet all inclusion criteria, and do not meet any exclusion criteria are eligible for enrollment~* Subject was compliant during participation in Study M15-566 (NCT02880956)~* Subject has an identified, reliable study partner who has frequent contact with the subject and who will provide information as to the subject's cognitive and functional abilities~Exclusion Criteria:~* The subject has any significant change in his/her medical condition since participation in Study M15-566 (NCT02880956) that could interfere with the subject's participation in Study M15-570, could place the subject at increased risk, or could confound interpretation of study results~* More than 8 weeks have elapsed since the subject received his/her last dose of study drug in Study M15-566 (NCT02880956)~* The subject is concurrently enrolled in another interventional clinical study involving a therapeutic agent with the exception of Study M15-566 (NCT02880956)

- Gender: ALL
- Minimum Age: 57 Years
- Maximum Age: 88 Years
- Healthy Volunteers: f

Study Arms:
- 300 mg/1000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received 300 mg tilavonemab in Study M15-566 receive 1000 mg tilavonemab in Study M15-570 via intravenous (IV) infusion every 4 weeks for up to 5.5 years.
- 1000 mg/1000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received 1000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
- 2000 mg/2000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received 2000 mg tilavonemab in Study M15-566 continue on the same dose in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.
- PBO/2000 mg Tilavonemab (Type: EXPERIMENTAL): Participants who received placebo (PBO) in Study M15-566 receive 2000 mg tilavonemab in Study M15-570 via IV infusion every 4 weeks for up to 5.5 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Infection's diagnosis while in the ICU~* Severe infection in any site (defined as the presence of sepsis/septic shock or bloodstream infection or pneumonia) associated with a positive culture by MRD-GNB (Acinetobacter baumannii complex, Pseudomonas aeruginosa, and Enterobacterales bacteria, only susceptible to carbapenems and/or polymyxins)~* Hemodynamically stable and afebrile (axillary temperature less than 37.8ºC) for at least 48 hours on day 7 of adequate antibiotic therapy~* Consent of the team providing care to the patient regarding their inclusion in the research~Exclusion criteria~* Inclusion in other experimental studies involving antimicrobial therapy~* Infections that have as the primary site: endocarditis/endovascular infection, necrotizing fasciitis, osteomyelitis, abdominal abscess or other abdominal infections requiring surgical intervention (except infections that have been treated surgically, with curative character within the first 3 days of appropriate antimicrobial therapy), central nervous system Infections, empyema, prosthetic infection;~* Immunosuppression defined as: neutrophil cells \<1000/mm³ in the current hospitalization, HIV/AIDS diagnosis with last CD4 count \<200/mm³, solid organ transplantation in the last year and/or need for increased immunosuppression due to acute rejection in the last year, hematopoietic stem cell transplantation in the last year, and/or current therapy for chronic graft-versus-host disease~* Positive blood cultures for the same pathogen within 48 hours prior to randomization, when collected~* Uncontrolled concomitant infection with another GNB (regardless of susceptibility profile)~* Previous inclusion in this study~* Known pregnancy~* Patient in palliative care who has already decided not to restart antimicrobials, if necessary, or hemodynamic support measures.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 7-day adequate antibiotic therapy (Type: EXPERIMENTAL): Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.
- 14-day adequate antibiotic therapy (Type: ACTIVE_COMPARATOR): Adequate antibiotic therapy is defined as antimicrobial treatment with at least one agent with in vitro susceptibility.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes according to Canadian Diabetes Association definition~* Initiation of a SU at baseline~* A1c: 7.0% to 10.0%~* Willing and able to comply with study procedures~Exclusion Criteria:~* Current or previous usage (during the last 3 months) of insulin or repaglinide~* Use of medication known to interfere with glucose metabolism~* Insulin requiring patient: catabolic state and/or ketonuria~* Currently using CGMS or within the last 3 months~* Recent severe hypoglycemia (\<3 months)~* Pregnancy or breast-feeding~* Limited life expectancy, high level of functional dependency, extensive coronary disease at high risk of short term ischemic events or multiple major co-morbidities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- T2DM at SU initiation (Type: None): T2DM newly prescribed a SU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of SCLC documented as TP53WT~* Disease must be measurable per RECIST Version 1.1~* Evidence of radiographic progression during or after at least one prior platinum-containing therapy with no curative therapy available. Subjects who have received only one prior line of therapy must not be candidates for platinum-based regimens at relapse.~* Subjects must have received a checkpoint inhibitor (PD-1 or PD-L1) unless contraindicated if checkpoint inhibitors are approved and available.~* ECOG ≤ 2~Exclusion Criteria:~* Symptomatic or uncontrolled central nervous system (CNS) metastases.~* Prior treatment with MDM2 inhibitors~* Chemotherapy, immune therapy, cytokine therapy, or any investigational therapy within 14 days prior to the first dose of study treatment~* Grade 2 or higher QTc prolongation (\> 480 milliseconds per NCI-CTCAE criteria, version 5.0)~* History of major organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)
- Arm 2 (Type: EXPERIMENTAL): KRT-232 180 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* At the time of eligibility for infusion of allodepleted T -cells patients must satisfy the criteria below:~* Patients with Fanconi anemia of all ages with severe aplasia (as evidenced by hypocellular bone marrow) who lack a suitable conventional related (i.e. 5/6 or 6/6 related) or 5/6 or 6/6 unrelated donor with at least 2 out of 3 of the following: a) ANC \< 500/mm3, b) reticulocytes \< 1% c) platelets \< 50,000/mm3~* Diagnosis of Fanconi anemia confirmed by studies of peripheral blood or bone marrow sensitivity to mitomycinC or DEB prior to stem cell transplant. Have received a related haploidentical CD34-selected peripheral blood stem cell transplant with evidence of a full or partial hematopoietic donor chimerism (\> 50%) in the peripheral blood.~Exclusion Criteria:~* Patients with a life expectancy (\< 6 weeks) limited by diseases other than FA~* Patients with active GVHD \> / = Grade II~* Patients with severe renal disease (i.e. creatinine greater than 3 X normal for age)~* Patients with severe hepatic disease (direct bilirubin greater than 3ug/dl or SGPT greater than 500ug/dl)~* Patients with a severe intercurrent infection~* Lansky scale \< 60 or Karnofsky \< 60

- Gender: ALL
- Minimum Age: None
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- CD34 selected haploidentical PBSCT (Type: EXPERIMENTAL): CD34 selected haploidentical PBSCT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Mesenchymal Stem Cells Under Basiliximab/Low Dose RATG to Induce Renal Transplant Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients~* Aged 18 or older~* Non-HLA identical with the donor (one or two haplotype mismatches)~* First kidney transplant~* Capable of understanding the purpose and risk of the study~* Written informed consent~Exclusion Criteria:~* MSC donor positive for HIV-1, HIV-2, HBV, HCV, Syphilis.~* Specific contraindication to MSC infusion~* Any clinical relevant condition that might affect study participation and/or study results~* Pregnant women and nursing mothers~* Unwillingness or inability to follow study protocol in the investigator's opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Men aged at least 18 years,~* Patients with ECOG performance status \<= 2 or Karnofsky Performance Status Scale \>= 70%,~* Estimated life expectancy more than 3 years,~* Diagnosis of prostate carcinoma,~* Indication for local RT in patients with prostatic cancer.~Exclusion Criteria:~* Crohn's disease, indeterminate colitis, ulcerative colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),~* Severe or symptomatic ischaemic colitis at baseline,~* Grade III internal haemorrhoids at baseline,~* High risk patients needing extended radiation therapy,~* Acute EORTC/RTOG lower GI toxicity score of \>=1 at baseline,~* Bacterial, amoebic, fungal, or viral infections of the gut,~* Tuberculosis, hypertension, infection, diabetes mellitus (included familiarly predisposition), active peptic ulcer, osteoporosis, glaucoma, or cataract, if careful medical monitoring is not ensured,~* Portal hypertension or liver cirrhosis,~* Abnormal hepatic function (ALT, AST or AP \> 2.5 x ULN),~* Known intolerance/hypersensitivity/resistance to study drug or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drug,~* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 2mg rectal budesonide per day for 8 weeks
- 2 (Type: PLACEBO_COMPARATOR): One application of placebo foam once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Hemophilia Inhibitor Prevention Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male children \>= 4 months and up to 4 years of age.~2. Severe hemophilia A (FVIII \< 0.01 U/ml).~3. No evidence of an inhibitor i.e. anti-FVIII \< 0.6 B.U.~4. No more than 3 FVIII exposures (Factor VIII concentrate, cryoprecipitate, or fresh frozen plasma), including circumcision.~Exclusion Criteria:~1. Acquired hemophilia or any bleeding disorder other than hemophilia A.~2. Treatment with clotting factor or emicizumab previously.~3. Use of an experimental drug(s).~4. Surgery anticipated in the next 48 weeks.~5. Life expectancy less than 5 years.~6. Parent/caretaker unable or unwilling to keep a personal diary of bleeding frequency and study drug treatment, make monthly visits and blood draws at weeks 4, 12, 24, 36, and 48.~7. Other illness, condition or reason in the opinion of the investigator that would make the patient unsuitable for the trial.

- Gender: MALE
- Minimum Age: 4 Months
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Eloctate (Type: ACTIVE_COMPARATOR): Arm A: Eloctate 65 IU/kg will be administered weekly by intravenous infusion in previously untreated children with severe hemophilia A beginning before the first bleed and continued up to 48 weeks.
- Emicizumab (Type: EXPERIMENTAL): Arm B: Emicizumab 1.5 mg/kg will be administered weekly by subcutaneous injection (following 3 mg/kg/wk x4 induction) in previously untreated children with severe hemophilia A beginning before the first bleed and continue up to 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval